Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial

Axicabtagene ciloleucel (axi-cel) demonstrated superior efficacy compared to standard of care as second-line therapy in patients with high-risk relapsed/refractory (R/R) large B cell lymphoma (LBCL) considered eligible for autologous stem cell transplantation (ASCT); however, in clinical practice, r...

Descripción completa

Detalles Bibliográficos
Autores principales: Houot, Roch, Bachy, Emmanuel, Cartron, Guillaume, Gros, François-Xavier, Morschhauser, Franck, Oberic, Lucie, Gastinne, Thomas, Feugier, Pierre, Duléry, Rémy, Thieblemont, Catherine, Joris, Magalie, Jardin, Fabrice, Choquet, Sylvain, Casasnovas, Olivier, Brisou, Gabriel, Cheminant, Morgane, Bay, Jacques-Olivier, Gutierrez, Francisco Llamas, Menard, Cédric, Tarte, Karin, Delfau, Marie-Hélène, Portugues, Cédric, Itti, Emmanuel, Palard-Novello, Xavier, Blanc-Durand, Paul, Al Tabaa, Yassine, Bailly, Clément, Laurent, Camille, Lemonnier, François
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10579056/
https://www.ncbi.nlm.nih.gov/pubmed/37710005
http://dx.doi.org/10.1038/s41591-023-02572-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10579056/
https://www.ncbi.nlm.nih.gov/pubmed/37710005
http://dx.doi.org/10.1038/s41591-023-02572-5

Ejemplares similares